Preclinical Anti-Tumor Activity Of Hexabody-Cd38 In Patient-Derived B Cell Lymphoma And Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra,Maarten L Janmaat,Peter Boross,Jeroen van den Brakel,Wessel ten Hagen,Sanne van Dooremalen,Sieto Bosgra, Bart Ecg De Goeij,Grietje Andringa,Laurens Kil,A Kate Sasser,Tahamtan Ahmadi,David Satijn,Esther Cw Breij

BLOOD（2020）

引用 1|浏览33

暂无评分

摘要

HexaBody®-CD38 (GEN3014) is a next-generation CD38-specific IgG1 molecule with a hexamerization-enhancing mutation that leads to highly efficient induction of complement-dependent cytotoxicity (CDC) upon binding to CD38 positive tumor cells. HexaBody-CD38 is designed to induce strong anti-tumor activity in patients with CD38-expressing hematological malignancies through CDC and other Fc-mediated effector functions.

查看译文

关键词

acute myeloid leukemia,cell lymphoma,anti-tumor,patient-derived

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要